KernalBiologics Revenue and Competitors
Estimated Revenue & Valuation
- KernalBiologics's estimated annual revenue is currently $3.4M per year.
- KernalBiologics's estimated revenue per employee is $112,000
Employee Data
- KernalBiologics has 30 Employees.
- KernalBiologics grew their employee count by 3% last year.
KernalBiologics's People
Name | Title | Email/Phone |
---|---|---|
1 | Co-Founder & President | Reveal Email/Phone |
2 | VP Business Development | Reveal Email/Phone |
3 | Director Convergence Science | Reveal Email/Phone |
4 | Chief Business Officer | Reveal Email/Phone |
5 | Senior Research Scientist | Reveal Email/Phone |
6 | Scientist | Reveal Email/Phone |
7 | Senior Computational Biologist | Reveal Email/Phone |
8 | Senior Associate Scientist, Synthetic Biology | Reveal Email/Phone |
9 | Principal Scientist | Reveal Email/Phone |
10 | Senior Scientist | Reveal Email/Phone |
KernalBiologics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $7.7M | 61 | N/A | N/A | N/A |
#2 | $2.8M | 29 | 38% | N/A | N/A |
#3 | $1.2M | 14 | -52% | N/A | N/A |
#4 | $3.5M | 31 | 3% | N/A | N/A |
#5 | $1190M | 5826 | -7% | $31M | N/A |
#6 | $25.9M | 168 | -2% | $193.6M | N/A |
#7 | $1.1M | 13 | 8% | N/A | N/A |
#8 | $0.5M | 7 | -22% | N/A | N/A |
#9 | $1.1M | 13 | 8% | N/A | N/A |
#10 | $10.9M | 78 | 0% | N/A | N/A |
What Is KernalBiologics?
Kernal creates mRNA therapies to cure diseases like COVID and cancer. Our mRNA therapies instruct specific cells on how to make their own drugs. With roots at MIT, Harvard and Big Pharma, our team previously built a successful Biotech company and has deep expertise in mRNA space.
keywords:N/AN/A
Total Funding
30
Number of Employees
$3.4M
Revenue (est)
3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.7M | 30 | 7% | N/A |
#2 | $6M | 30 | 3% | N/A |
#3 | $6.5M | 30 | -23% | N/A |
#4 | $15M | 30 | -60% | N/A |
#5 | $6M | 30 | -3% | N/A |